Literature DB >> 2378856

Effects of topical timolol (0.5%) and betaxolol (0.5%) on corneal sensitivity.

S S Weissman1, P A Asbell.   

Abstract

There are conflicting reports on the propensity of topical beta blockers to produce corneal anaesthesia. We measured corneal sensitivity thresholds quantitatively for 10 minutes following the administration of one drop of topical timolol maleate (0.5%), betaxolol hydrochloride (0.5%), or saline in 30 eyes of 18 normal subjects in a randomised, double-masked study. Most subjects had insignificant changes in corneal sensitivity thresholds. We identified, however, a subgroup of four subjects (five eyes) that had a marked and prolonged increase of corneal sensitivity threshold (corneal anaesthesia) after timolol (three eyes) and betaxolol (two eyes). The group mean age of these 'responders' (49.0 years) was significantly greater (p less than 0.005) than that of the non-responders (35.0). We recommend periodic measurements of corneal sensitivity in older patients receiving topical timolol or betaxolol, especially when given in higher concentrations, to identify responders, who may be at risk of developing keratitis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2378856      PMCID: PMC1042150          DOI: 10.1136/bjo.74.7.409

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  24 in total

1.  Direct evidence for an interaction of beta-adrenergic blockers with the 5-HT receptor.

Authors: 
Journal:  Nature       Date:  1977-05-19       Impact factor: 49.962

2.  A HISTOCHEMICAL STUDY OF THE ADRENERGIC AND CHOLINERGIC INNERVATION OF THE ANTERIOR SEGMENT OF THE RABBIT EYE.

Authors:  A LATIES; D JACOBOWITZ
Journal:  Invest Ophthalmol       Date:  1964-12

Review 3.  Perspectives in adrenergic beta-receptor blockade.

Authors:  J D Fitzgerald
Journal:  Clin Pharmacol Ther       Date:  1969 May-Jun       Impact factor: 6.875

4.  Corneal anaesthesia after topical treatment with timolol maleate. A case report.

Authors:  B Calissendorff
Journal:  Acta Ophthalmol (Copenh)       Date:  1981-06

5.  Betaxolol. A new beta-adrenergic blocking agent for treatment of glaucoma.

Authors:  A R Berrospi; H M Leibowitz
Journal:  Arch Ophthalmol       Date:  1982-06

6.  Comparative dromotropic activity of timolol and propranolol in anesthetized dogs.

Authors:  P Jaillon; J Heckle; J Weissenburger; G Cheymol
Journal:  Eur J Pharmacol       Date:  1978-01-15       Impact factor: 4.432

7.  Adverse reactions from timolol administration.

Authors:  E M Van Buskirk
Journal:  Ophthalmology       Date:  1980-05       Impact factor: 12.079

8.  Neural serotonin stimulates chloride transport in the rabbit corneal epithelium.

Authors:  S D Klyce; K A Palkama; M Härkönen; W S Marshall; S Huhtaniitty; K P Mann; A H Neufeld
Journal:  Invest Ophthalmol Vis Sci       Date:  1982-08       Impact factor: 4.799

9.  Substance P-immunoreactive nerves in the human cornea and iris.

Authors:  K Tervo; T Tervo; L Eränkö; A Vannas; A C Cuello; O Eränkö
Journal:  Invest Ophthalmol Vis Sci       Date:  1982-11       Impact factor: 4.799

10.  Corneal anesthesia after timolol maleate therapy.

Authors:  E M Van Buskirk
Journal:  Am J Ophthalmol       Date:  1979-10       Impact factor: 5.258

View more
  16 in total

1.  Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5% timolol v 0. 12% unoprostone.

Authors:  J Shimazaki; K Hanada; Y Yagi; J Yamagami; M Ishioka; S Shimmura; K Tsubota
Journal:  Br J Ophthalmol       Date:  2000-11       Impact factor: 4.638

2.  Effects of long-term topical anti-glaucoma medications on meibomian glands.

Authors:  Reiko Arita; Kouzo Itoh; Shuji Maeda; Koshi Maeda; Ayumu Furuta; Atsuo Tomidokoro; Makoto Aihara; Shiro Amano
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-02-18       Impact factor: 3.117

3.  Conjunctival and corneal sensitivity in patients under topical antiglaucoma treatment.

Authors:  Lorena Romero-Díaz de León; Jorge-Emmanuel Morales-León; Jasbeth Ledesma-Gil; Alejandro Navas
Journal:  Int Ophthalmol       Date:  2015-08-14       Impact factor: 2.031

Review 4.  Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue.

Authors:  J Javier Servat; C Robert Bernardino
Journal:  Drugs Aging       Date:  2011-04-01       Impact factor: 3.923

5.  Corneal ulceration in the elderly in Hyderabad, south India.

Authors:  D Y Kunimoto; S Sharma; P Garg; U Gopinathan; D Miller; G N Rao
Journal:  Br J Ophthalmol       Date:  2000-01       Impact factor: 4.638

6.  Effects of a long-acting ophthalmic formulation of carteolol containing alginic acid on the corneal epithelial barrier function and water retentive effect.

Authors:  Naoto Tokuda; Jun Inoue; Izumi Yamazaki; Satoki Ueno; Sigeki Fujisawa
Journal:  J Ocul Pharmacol Ther       Date:  2012-01-04       Impact factor: 2.671

7.  Effect of topical beta blockers on corneal epithelial wound healing in the rabbit.

Authors:  J J Reidy; J Zarzour; H W Thompson; R W Beuerman
Journal:  Br J Ophthalmol       Date:  1994-05       Impact factor: 4.638

8.  Effects of timolol-related ophthalmic solutions on cultured human conjunctival cells.

Authors:  Kazuhide Kawase; Wenzhong Lin; Yumiko Aoyama; Tetsuya Yamamoto; Masamitsu Shimazawa; Hideaki Hara
Journal:  Jpn J Ophthalmol       Date:  2010-12-30       Impact factor: 2.447

9.  Incidence, severity and factors related to drug-induced keratoepitheliopathy with glaucoma medications.

Authors:  Takeo Fukuchi; Kimiko Wakai; Kieko Suda; Tomoko Nakatsue; Hideko Sawada; Hiroaki Hara; Jun Ueda; Takayuki Tanaka; Akiko Yamada; Haruki Abe
Journal:  Clin Ophthalmol       Date:  2010-04-26

Review 10.  Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages.

Authors:  Gábor Holló; Andreas Katsanos; Kostas G Boboridis; Murat Irkec; Anastasios G P Konstas
Journal:  Drugs       Date:  2018-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.